Additionally, in Luminal A and B breast cancer subtypes, low BCAR3 expression, alongside BCAR1, correlates with poor prognosis, adverse lymph node status, and diminished response to hormonal therapy, indicating potential as markers for endocrine therapy resistance [9]. This evidence concerns the gene BCAR3 and breast carcinoma.